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Abstract 
Mitochondrial fusion and fission is a dynamic process critical for the maintenance of 
mitochondrial function and cell viability.  During excitotoxicity neuronal mitochondria 
are fragmented but the mechanism underlying this process is poorly understood.  Here 
we show that Mfn2 is the only member of the mitochondrial fusion/fission machinery 
whose expression is reduced in in vitro and in vivo models of excitotoxicity. Whereas in 
cortical primary cultures Drp1 recruitment to mitochondria plays a primordial role in 
mitochondrial fragmentation in an early phase that can be reversed once the insult has 
ceased, Mfn2 downregulation intervenes in a delayed mitochondrial fragmentation 
phase that progresses even when the insult has ceased. Downregulation of Mfn2 results 
in vulnerability of neurons to subtoxic doses of NMDA due to mitochondrial 
dysfunction and altered calcium homeostasis. We found that transcription factor MEF2 
regulates basal Mfn2 expression in neurons, and that excitotoxicity-dependent 
degradation of MEF2 causes Mfn2 downregulation. Thus, Mfn2 reduction is a late 
event in excitotoxicity and its targeting may help to reduce excitotoxic damage and 
increase the currently short therapeutic window in stroke.  
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Introduction 
Glutamate is the main excitatory neurotransmitter in the central nervous system. It plays 
an essential role in development, synaptic plasticity and neuronal survival but sustained 
elevated levels of extracellular glutamate kill neurons in a process called excitotoxicity 
(Arundine & Tymianski, 2003). Excitotoxicity takes place in both chronic neurological 
diseases, such as Huntington’s and Alzheimer’s disease, and in acute episodes such as 
traumatic brain injury and ischemic stroke.   The NMDA receptor (NMDAR) is the 
main ionotropic glutamate receptor in the CNS and the excessive flux of Ca
2+
 that 
passes through it is a major cause of excitotoxicity. Despite evidence indicating a 
crucial role of NMDAR activation in brain damage during stroke, clinical trials with 
NMDAR blockers have failed because of poor tolerance and efficacy (Ikonomidou & 
Turski, 2002; Muir, 2006). In contrast to excessive NMDAR activity that causes cell 
death, its physiological activity triggers pro-survival signals that may play a role in 
promoting recovery and preventing delayed neuronal loss in the penumbra (Ikonomidou 
& Turski, 2002; Lo, 2008). Thus, future therapies to reduce excitotoxicity must target 
pro-death events downstream of NMDAR without affecting the pro-survival signals.  
Several mechanisms are implicated in cell death triggered by Ca
2+
 influx through 
NMDAR.  Mitochondrial dysfunction caused by excessive Ca
2+
 uptake acts as a 
signaling hub for many pro-death events (Almeida et al, 1999; Reynolds & Hastings, 
1995; Soriano et al, 2008; Stout et al, 1998; Yu et al, 2002).   
Mitochondria are dynamic organelles that constantly fuse and divide, changing shape 
and localization. The equilibrium between fission and fusion is important for 
mitochondrial function, which is not only limited to supplying energy to the cell, but 
also intervenes in anabolic and catabolic biochemical pathways and the regulation of 
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Ca
2+
 homeostasis, and is a key regulator of cell death progression.  The core 
mitochondrial fusion and fission machineries are formed by a group of dynamin-related 
large GTPases (Liesa et al, 2009; Westermann, 2010).  
Inner mitochondrial membrane fusion is mediated by Opa1. Two Mitofusins (Mfn), 
Mfn1 and 2, mediate mitochondrial outer membrane fusion. Mfn1 and Mfn2 display 
high homology (81%) and around 60% identity, but nonetheless they have non-
redundant roles (de Brito & Scorrano, 2008b; Liesa et al, 2009). In addition to its fusion 
role Mfn2 localization in the ER is necessary to maintain the reticular morphology of 
the ER and control the ER–mitochondria interaction (de Brito & Scorrano, 2008a).  
Mfn2 may also play a role in neuronal mitochondrial trafficking, and disruption of this 
function can lead to axon degeneration (Baloh et al, 2007; Misko et al, 2012). 
Mitochondrial fission is mediated by Drp1.  Drp1 is mainly cytoplasmic and its 
translocation to mitochondria, recruited by Fis1 and/or Mff, is essential for 
mitochondrial fission. Drp1 is subjected to several posttranscriptional modifications, 
including phosphorylation, ubiquitination, SUMOylation and nitrosylation, which can 
either activate or repress fission activity (Cho et al, 2010; Oettinghaus et al, 2012).   
Although mitochondrial fission per se does not cause cell death, fragmentation of 
mitochondria has been shown to play a key role in cell death progression. Mitochondrial 
fragmentation occurs early in apoptosis and can be delayed by expressing a dominant 
negative Drp1 (Breckenridge et al, 2003; Frank et al, 2001).  Recently, Drp1 has also 
been implicated in the induction of necrosis (Wang et al, 2012). Mutations in Mfn2 are 
the most commonly identified cause of Charcot-Marie-Tooth type 2 (CMT2), a 
dominantly inherited disease characterized by degeneration of peripheral sensory and 
motor axons (Zuchner et al, 2004). Purkinje cells require Mfn2 but not Mfn1 for 
dendritic outgrowth, spine formation, and cell survival (Chen et al, 2007). 
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Mitochondrial fragmentation is an early event that occurs before the release of 
mitochondrial proteins and neurite degeneration in an in-vivo animal model of stroke 
(Barsoum et al, 2006). Despite the importance of mitochondrial dynamics in cell death 
progression the exact mechanism that underlies the mitochondrial fragmentation in 
excitotoxicity is incompletely understood. In this study, we assessed how the proteins of 
the core mitochondrial fussion/fision machinery are regulated in excitotoxicity. We 
found that Mfn2 levels are reduced in both in-vitro and in-vivo models of excitotoxicity,  
via MEF2 degradation that, by acting on the Mfn2 promoter, regulates basal levels of 
Mfn2. Downregulation of Mfn2 causes mitochondrial dysfunction and altered Ca
2+
 
homeostasis, which sensitizes neurons to cell death. 
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Results 
Mfn2 protein expression is reduced in excitotoxicity 
Mitochondrial dynamics plays a pivotal role in cell death. Changes in mitochondrial 
morphology have been observed in excitotoxicity but the precise mechanism has not 
been fully defined. For a better understanding of the mechanism by which mitochondria 
are fragmented during excitotoxicity we exposed primary cortical cultures to moderate 
doses (30 M)  of the glutamate receptor agonist NMDA over a time course of 1, 2, 4 
and 8 hours  and analyzed the expression of the proteins of the mitochondrial 
fission/fusion machinery. During the first 2 hours after NMDA application there were 
no significant changes in either fusion or fission proteins but after 4 hours of NMDA 
treatment we observed a 40% reduction in the fusion protein Mfn2 with no changes in 
the other fusion proteins, Mfn1 and Opa1. Surprisingly, Drp1 showed a tendency to 
reduce its protein levels during the first hour and reached a plateau thereafter (Fig. 
1A,B).  To rule out the possibility that changes in the expression of mitochondrial 
fission/fusion protein were due to changes in mitochondrial mass, volume normalization 
was also performed with the mitochondrial protein porin, achieving similar results (Fig. 
S1A). 
To check the pathophysiological relevance of these in vitro findings we created an 
ischemic insult in P12 rats by permanent middle cerebral artery occlusion followed by 
90 minutes occlusion of the carotid artery.  During an ischemic episode, glutamate 
levels build up as a result of synaptic release and impaired and/or reversed uptake 
mechanisms (Camacho & Massieu, 2006), which induce excessive activation of NMDA 
glutamate receptors (NMDARs) and Ca
2+
-mediated cell death (Arundine & Tymianski, 
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2003). We analyzed the expression of the mitochondrial fusion/fission machinery at 
several time points after the ischemic insult. The results were similar to those found in 
vitro. Two hours after restoration of the carotid blood flow, i.e. 3.5 hours after ischemia 
began, Mfn2 protein levels began to decline, and reached a significant 50% reduction 6 
hours after the restoration of carotid blood flow (Fig. 1C,D and Fig. 1SB).  Drp1 also 
showed a slight but significant reduction (20%) 2 hours after the restoration of blood 
flow. Neither of the other mitochondrial fusion proteins (Mfn1 and Opa1) showed 
changes in levels during the 24 hours after the onset of ischemia. Thus, our in vitro 
neuronal cultures recapitulate well the excitotoxic in vivo model. 
 
Activation of Drp1 induces mitochondrial fragmentation 
We observed Mfn2 downregulation 4 hours after initiating the insult, but nonetheless 
the kinetics of excitotoxicity-mediated mitochondrial fragmentation has been reported 
to be fast (Barsoum et al, 2006; Rintoul et al, 2003; Young et al, 2010). To clarify this, 
we analyzed the mitochondrial morphology of those neurons expressing RFP targeted to 
the mitochondrial matrix (mtRFP) that were still alive (as shown by nuclear DAPI 
staining; Fig. 2A) after NMDA treatment of different durations. Untreated neurons 
contained mainly well-connected tubular mitochondria (60%). After only 30–60 
minutes of NMDA application most of the neurons contained globular mitochondria 
that remained intact for the following 2 hours, with a small amount of additional 
fragmentation 4 hours after NMDA treatment (Fig. 2B). Thus, although the secondary 
fragmentation correlates with the diminished Mfn2 expression it is unlikely that Mfn2 is 
responsible for the first, early phase of mitochondrial fragmentation.    
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We observed a tendency for a decline in Drp1 in excitotoxicity (Fig. 1). Nonetheless, 
what determines Drp1 activity is its subcellular localization. Drp1 is mainly cytosolic 
and by posttranslational modifications it is recruited to the mitochondria by Mff and/or 
Fis1 where it promotes fission (Gandre-Babbe & van der Bliek, 2008; James et al, 2003; 
Otera et al, 2010; Yoon et al, 2003). In basal conditions GFP-Drp1 transfected neurons 
showed a weak diffuse signal within the neuron. Application of NMDA for 1 hour 
produced a strong punctuate signal that co-localized with mitochondria (Fig. 2C). 
Overexpression of a mutant form of Drp1 (Drp1-K38A), which acts as a dominant 
negative (Smirnova et al, 1998), or the Drp1 inhibitor mdivi-1, significantly attenuated 
the NMDA-mediated mitochondrial fragmentation during the first hour of NMDA 
treatment (Fig. 2D). Excitotoxic NMDA stimulates neuronal nitric oxide production, 
which nitrosylates and activates Drp1 (Barsoum et al, 2006; Cho et al, 2009). 
Consequently, inhibition of the nitric oxide synthase with 7-Nitroindazole (7-Ni) 
blocked the mitochondrial fragmentation to the same extent as the mutant Drp1-K38A 
or mdivi-1 (Fig. 2D). These experiments indicate that NO-mediated Drp1 activation 
plays a key role in mitochondrial fragmentation during excitotoxicity, although other 
mechanisms may also be involved.  
 
 Mfn2 intervenes in an irreversible late phase of mitochondrial fragmentation 
Previous studies have shown that glutamate- and nitric–oxide-mediated mitochondrial 
fragmentation are amenable to restoration once the stimulus has ceased (Barsoum et al, 
2006; Rintoul et al, 2003). Thereby, we decided to test the reversibility of mitochondrial 
morphology in our system.  We applied NMDA for 1 hour and then washed out the 
NMDA and returned to fresh media. We observed that the mitochondrial tubular 
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morphology recovered 90 minutes after replacing the media but that after 180 minutes 
the mitochondria fragmented once again (Fig. 3A). The events that triggered the decline 
in Mfn2 levels began during the first hour of NMDA exposure since subsequent 
washout of the agonist did not block the reduction in Mfn2 (Fig. 3B).  Because the 
delayed phase of mitochondrial fragmentation correlates with the reduction in Mfn2 
protein levels (Fig. 1A, Fig. 2B and Fig. 3A, B) we reasoned that the reduction in Mfn2 
levels in excitotoxicity intervenes in late mitochondrial fission.  We knocked down 
Mfn2 using shRNA, which targets its sequence (shMfn2).  Importantly, shMfn2 reduced 
Mfn2 protein levels by around 50%, resembling the reduction observed in excitotoxicity 
(Fig. 3C).  As expected, knockdown of Mfn2 was sufficient to cause mitochondrial 
fragmentation (Fig. 3D and Fig. S2A, C). Another two shRNAs targeting Mfn2 at 
different sequences also showed mitochondrial fragmentation (Fig. S2B, C). 
Conversely, exogenous expression of Mfn2 significantly blocked the late phase of 
mitochondrial fragmentation after NMDA washout (Fig. 3E). 
All of this indicates that excitotoxicity promotes mitochondrial fragmentation by at least 
two mechanisms, a fast mechanism relying on Drp1 activation that lasts while the insult 
is present, and a late mechanism dependent on the reduction in Mfn2 expression that 
takes place hours after the insult is generated and persists independently of the removal 
of the insult. 
 
Mfn2 downregulation causes mitochondrial dysfunction and altered Ca
2+
 
homeostasis and sensitizes neurons to excitotoxic damage  
The therapeutic window in ischemic stroke is only 4.5 hours from the onset of 
symptoms (Zhang et al, 2012). Thus, it would be of great interest to find novel late 
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events for therapeutic targeting. The fact that we observed a decline in Mfn2 protein 
levels 4 hours after excitotoxicity started, and given that in addition to its mitochondrial 
fusion activity Mfn2 has unique properties that are not shared with Mfn1, such as 
activating mitochondrial oxidative metabolism or tethering of mitochondria with the ER 
regulating Ca
2+
 homeostasis  (Bach et al, 2003; Baloh et al, 2007; de Brito & Scorrano, 
2008a; Pich et al, 2005), led us to hypothesize that Mfn2 reduction could play an active 
role in the progression of excitotoxic damage. Thus, we determined how lower levels of 
Mfn2 could affect mitochondrial function. We first determined mitochondrial 
membrane potential as an indicator of mitochondrial function. In concordance with 
observations made in other cell types (Bach et al, 2003; Soriano et al, 2006), 
mitochondria in Mfn2 KD neurons had around 15%  lower mitochondrial membrane 
potential than control transfected cells, indicating impaired mitochondrial function (Fig. 
4A). The impairment of mitochondrial function was exacerbated when neurons were 
challenged with doses of NMDA at the threshold of toxicity. Application of 15 M 
NMDA produced a moderate loss in mitochondrial membrane potential that was greatly 
enhanced in Mfn2 KD neurons (Fig. 4A).  
Because mitochondria play a key role in buffering the increase in cytosolic Ca
2+
 
produced during excitotoxicity, which depends on proper mitochondrial membrane 
potential (Nicholls, 2009), we reasoned that Ca
2+
 homeostasis may be impaired in Mfn2 
KD neurons. Under basal conditions Mfn2 KD neurons have a slightly higher 
cytoplasmic Ca
2+
 concentration (Fig. 4B, C). The application of NMDA produced an 
increase in cytosolic Ca
2+
 that was much greater in Mfn2 KD cells (Fig. 4B, C). Calpain 
is a Ca
2+
 dependent Ser protease that has been implicated in excitotoxic cell death. We 
analyzed spectrin cleavage after NMDA as a measure of calpain activity and found that 
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Mfn2 KD neurons showed increased calpain activation consistent with the increased 
cytoplasmic Ca
2+
 concentration (Fig. S3A).  
Given that reduced levels of Mfn2 had a great impact on mitochondrial membrane 
potential and Ca
2+
 handling when neurons were treated with low doses of NMDA, we 
wondered whether the reduction in Mfn2 could have consequences for cell viability. 
This was indeed the case, as knockdown of Mfn2 sensitized neurons to subtoxic doses 
of NMDA (Fig. 4D). Another two shRNAs targeting Mfn2 at different sequences also 
showed sensitization to subtoxic doses of NMDA, ruling out the possibility of an off-
target effect (Fig. S3B). In contrast, although overexpression of Mfn2 slightly increased 
neuronal cell death, indicating the importance of fine regulation, it reduced NMDA-
induced neuronal death by almost two fold (Fig. S3C, D).    
Together, these data support the notion that a reduction in Mfn2 causes mitochondrial 
malfunction, which increases the vulnerability of neurons to excitotoxic cell death. 
 
Mfn2 is regulated at the transcriptional level in excitotoxicity 
Next we investigated the mechanism by which Mfn2 expression is reduced in 
excitotoxicity. It is well known that Mfn2 is degraded by the proteasome in a Parkin 
dependent manner (Chan et al, 2011; Tanaka et al, 2010). We wondered whether the 
decrease in Mfn2 levels in excitotoxicity was due to its proteasomal degradation. 
Surprisingly, we found that pretreatment of neurons with the proteasome inhibitor MG-
132 did not abolish the NMDA dependent reduction in Mfn2 (Fig. 5A, B) even when 
the concentration of MG-132 used (10 M) promoted the accumulation of ubiquitinated 
proteins and effectively blocked the CCCP mediated degradation of Mfn2 (Fig. S4A 
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and B). Therefore we can conclude that excitotoxic dependent downregulation of Mfn2 
is not dependent on proteasomal degradation.  
Excitotoxicity causes changes in transcriptional programs (Cook et al, 2012; Zhang et 
al, 2007), which could be consistent with the slow effect of NMDA on Mfn2 
expression. We investigated whether Mfn2 reduction was due to changes in its gene 
expression. Mfn2 gene expression showed an initial increase during the first hour after 
NMDA application, probably a defensive response to malfunctioning mitochondria. 
Mfn2 gene expression started to decrease during the second hour, reaching a plateau 
after 4 hours that remained steady for up to 8 hours of treatment and correlated with the 
time course of protein expression (Fig. 5C).  The repression of Mfn2 expression is 
specific since Mfn1 and SESN2 expression were not affected by NMDA treatment (Fig. 
5C). These data indicate that Mfn2 gene expression is downregulated during 
excitotoxicity, but do not rule out the possibility that other proteases could participate in 
the excitotoxicity mediated reduction in Mfn2. To verify that a transcriptional change is 
the main mechanism by which Mfn2 expression is reduced in excitotoxicity, we used 
the transcriptional inhibitor actinomycin D or the translational inhibitor cycloheximide. 
As expected, the use of these inhibitors reduced Mfn2 protein levels but additional 
application of NMDA did not produce a further reduction in Mfn2, as would be 
expected if a proteolytic process was responsible for NMDA-mediated Mfn2 
downregulation (Fig. 5 D, E). Thus, all these sets of experiments clearly indicate that 
the main mechanism by which NMDA mediates Mfn2 downregulation is at the 
transcriptional level rather than being a proteolytic process. 
 
Excitotoxicity mediated Mfn2 downregulation depends on MEF2  
13 
 
MEF2(A–D) are transcription factors that play an important role in neuronal 
development and  viability (Flavell et al, 2008; Mao et al, 1999). During excitotoxicity 
MEF2s are cleaved by caspases generating DNA binding domains without the 
transactivation domain, which acts as a dominant negative interfering form (Li et al, 
2001; Okamoto et al, 2002). Time-course analysis of protein extracts of cortical neurons 
exposed to NMDA or brains from rats that have been subjected to ischemia showed a 
reduction in MEF2A in a pattern that correlated well with Mfn2 expression (Fig. 6 A, 
B). All this raises the possibility that NMDA-dependent cleavage of MEF2s may be 
responsible for Mfn2 downregulation in excitotoxicity. Neurons expressing the DNA 
binding domain of MEF2 without the transactivation domain showed reduced 
expression of Mfn2 protein and mRNA (Fig. 6C, F).  Consistent with the reduced 
expression of Mfn2, MEF2-DN transduced neurons contained fragmented mitochondria 
whose morphology was restored by expressing exogenous Mfn2 (Fig. 6D). 
Mitochondria of MEF2-DN expressing neurons showed reduced mitochondrial 
membrane potential that could be raised by overexpression of Mfn2 (Fig. 6E). All these 
results demonstrate that Mfn2 expression is regulated by MEF2 but do not answer the 
question of whether MEF2 degradation is the main factor mediating Mfn2 
downregulation in excitotoxicity. Thus, we analyzed Mfn2 mRNA in neurons 
transduced with AAV coding MEF2-DN and observed that Mfn2 downregulation with 
respect to its control (GFP transduced) neurons was not additively enhanced when 
NMDA was applied, suggesting that they act in a common pathway  (Fig. 6F). 
Together, these data demonstrate a crucial role of MEF2 in the excitotoxicity-dependent 
downregulation of Mfn2. 
 
MEF2 directly regulates basal Mfn2 expression in neurons 
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Next, we investigated whether MEF2 could directly regulate Mfn2 expression. In 
promoter reporter assays MEF2-DN repressed the activity of human Mfn2 promoter in 
neurons but did not repress the activity of SESN2 promoter, consistent with the 
unchanged expression of SESN2 in excitotoxicity (Fig. 7A).  The effect of MEF2-DN 
on the Mfn2 promoter was neuron specific since it did not affect the promoter activity in 
10T1/2 fibroblasts, a cell line with far less expression of MEF2 than neurons (Fig. 7A 
and Fig. S5A). These results are consistent with a prevalent role of MEF2 in the 
regulation of basal Mfn2 expression in neurons.  
Next we determined the cis-elements involved in the effects of MEF2 on the 
transcriptional activity of the Mfn2 promoter. In agreement with the low expression of 
MEF2 in 10T1/2 cells, over-expression of MEF2A strongly activated the Mfn2 
promoter (Fig. 7B). Deletion analysis of the Mfn2 promoter identified the MEF2A 
activated region as being between -1332 and -668 relative to the transcription start site 
(Fig. 7B). Further deletions revealed that the response region was located between -
1030 and -862 (not shown). The MEF2 transcription factors bind DNA in A/T rich 
sequences (Black & Olson, 1998). The sequence -1030/-862 contains two putative 
MEF2 binding sites (Fig. S5B). In order to show the functional role of these putative 
MEF2 binding sites we disrupted the A/T rich sequence, introducing C and G by 
directed mutagenesis (Fig. S5B). Mutation of BOX 1 did not modify the MEF2A 
induced promoter activation but mutation of BOX 2 cancelled the effect of MEF2A 
(Fig. 7C). These results indicated that BOX 2 is the cis-element required for MEF2A 
mediated activation of the Mfn2 promoter.  
Since MEF2A was able to trans-activated the Mfn2 promoter, EMSA experiments were 
performed in order to ascertain whether MEF2A was bound to BOX 2. A DNA 
fragment encompassing BOX 2 was radioactively labeled, and incubated with nuclear 
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extracts of HeLa cells overexpressing MEF2A. MEF2A bound BOX 2 containing 
probe, inducing the typical double band mobility shift (Santalucia et al, 2001), but did 
not bind the mutated probe (Fig. 7D). The retarded bands were competed with a 25- or 
100-fold excess of unlabeled oligonucleotide probe or 100-fold excess of a probe of the 
Glut4 promoter that has previously been shown to bind MEF2 (Santalucia et al, 2001), 
whereas the cold mutated probe was unable to compete with the retarded bands. In 
addition, an antibody against MEF2 supershifted the complex (Fig. 7E). The binding of 
MEF2A to the Mfn2 promoter in vivo was confirmed by chromatin 
immunoprecipitation assays (ChIP). To this end, cells were transfected with MEF2A, 
extracts were immunoprecipitated with an anti-MEF2A antibody and a fragment of the 
promoter containing BOX 2 was amplified by PCR (-1004/-828). Immunoprecipitates 
specifically amplified the Mfn2 promoter, indicating the in vivo binding of MEF2A to 
the Mfn2 promoter (Fig. 7F).  
Bioinformatic analysis of 2.5 kb of the rat Mfn2 promoter identified that there were four 
putative MEF2 binding sites in the region spanning -2313/-1983 (Fig. S5C). We 
designed primers to amplify within this region and performed ChIP with anti-MEF2A 
antibody in rat cortical neurons unstimulated or stimulated with NMDA for 4 hours. We 
found that under basal conditions MEF2 was bound to this region but after NMDA 
stimulation there was no enrichment of this region with the chromatin 
immunoprecipitate (Fig. 7G). These observations support the hypothesis that MEF2 
regulates basal transcription of Mfn2 in neurons and as a consequence of MEF2 
degradation Mfn2 transcription is downregulated in excitotoxicity (Fig. 8). 
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Discussion 
Mitochondria are dynamic organelles that continuously fuse and divide. Changes in 
mitochondrial dynamics have profound effects on mitochondrial function and therefore 
mitochondrial viability.  Here, we have studied mitochondrial dynamics in 
excitotoxicity. Our findings show that most of the mitochondrial fragmentation occurs 
within the first hour following the excitotoxic insult.  This early phase depends partially 
on Drp1mitochondrial translocation and lasts as long as the stimulus is present. Four 
hours after initiation of the insult, and regardless of its removal, delayed mitochondrial 
fragmentation that correlates with the reduction in Mfn2 protein levels due to its 
transcriptional downregulation occurs. Loss of Mfn2 impairs mitochondrial function 
and sensitizes neurons to excitotoxic damage.  
Mechanisms of mitochondrial fragmentation in excitotoxicity 
Drp1 is subjected to several posttranslational modifications that regulate its fission 
activity. Neuronal depolarization activates CaMKI, which phosphorylates Drp1 at Ser 
600, promoting mitochondrial fragmentation that is reversible once neurons repolarize 
(Han et al, 2008). The reversibility of Drp1-mediated mitochondrial fragmentation has 
also been observed in pathological conditions.  Mitochondrial fragmentation induced by 
NO donors is a rapid and reversible process (Barsoum et al, 2006). Ca
2+
 influx through 
the NMDA receptor produces NOS activation, which has been implicated in nitrosative 
stress and cell death (Sattler et al, 1999). Nitrosative stress causes S-nitrosylation of 
Drp1 at Cys644, which enhances mitochondrial fission (Cho et al, 2009).  In agreement 
with previous reports (Barsoum et al, 2006), we show that NOS inhibition partially 
blocks NMDA-mediated mitochondrial fragmentation.  The degree of inhibition of the 
mitochondrial fragmentation achieved by NOS inhibitors is similar to that achieved 
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using genetic and pharmacological inhibitors of Drp1. That suggests the involvement of 
a mechanism other than Drp1 in the early phase of mitochondrial fragmentation. Opa1 
is cleaved in a mitochondrial membrane potential dependent manner, promoting 
mitochondrial fission (Griparic et al, 2007; Ishihara et al, 2006; Song et al, 2007), but 
we were unable to detect changes in the proportion of short and long forms of Opa1 in 
excitotoxicity, either in vitro or in vivo.  Another possibility is that excitotoxicity could 
promote the modification of lipids, which has been shown to affect mitochondrial 
dynamics ((Choi et al, 2006)). The possibility that as yet unknown posttranscriptional 
modifications inhibit the fusion machinery in excitotoxic conditions cannot be ruled out 
either.  
Our data also indicate that Mfn2 intervenes in the delayed phase of mitochondrial 
fragmentation. Cultured rat primary cortical neurons exposed to excitotoxic doses of 
NMDA and in vivo middle cerebral artery occlusion in rats show reduced expression of 
Mfn2 but no changes in Mfn1 or Opa1. During the preparation of the manuscript two 
independent studies confirmed the downregulation of Mfn2 in excitotoxicity. Primary 
rat cortical neurons exposed to 3 hours of oxygen and glucose deprivation (OGD), 
another model of excitotoxicity, also produced a reduction in Mfn2 protein with no 
changes in Opa1 and an increase in Mfn1 expression (Wappler et al, 2013). In an in vivo 
study, a reduction in Mfn2, and also of Opa1 expression, was observed in mice 
subjected to MCAO (Kumari et al, 2012).  
 
Dependence of neurons on Mfn2 
Mfn1 can compensate for some but not all of the functions of Mfn2. Analysis of Mfn2 
and Mfn1 knockout mice indicates that they have both redundant and distinct functions 
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(Chen et al, 2003; Chen et al, 2007). Unlike Mfn1, a lack of or defects in Mfn2 have a 
great impact on neuronal viability. Mfn2 mutations have been found to cause the 
dominantly inherited neurological disease Charcot-Marie-Tooth type 2A (CMT2A) 
(Zuchner et al, 2004). Defects in mitochondrial mobility and fusion have been proposed 
as the mechanism by which Mfn2 mutations cause CMT2A but this has not been fully 
established (Baloh et al, 2007). Mfn2 is required for postnatal development of the 
cerebellum (Chen et al, 2007). Conditional dopaminergic Mfn2 knockout neurons show 
that Mfn2, but not Mfn1, is essential for striatal projections and proper nigrostriatal 
circuit function (Lee et al, 2012; Pham et al, 2012). 
Our results show that neurons with Mfn2 knocked down to levels similar to those 
produced in excitotoxicity have impaired mitochondrial function. Independently of its 
fusion activity, Mfn2 repression in myotubes impairs mitochondrial oxidative 
metabolism and mitochondrial membrane potential by interacting with and regulating 
the expression of some subunits of OXPOS complexes I, II, III and V (Bach et al, 2003; 
Pich et al, 2005; Segales et al, 2013). Mitochondria play a crucial role in regulating Ca
2+
 
homeostasis. Mitochondrial Ca
2+
 uptake is mediated by mitochondrial inner membrane 
mitochondrial calcium uniporter (MCU), which is driven by mitochondrial membrane 
potential. Mitochondrial Ca
2+
 uptake uses the proton-motive force, thus competing with 
mitochondrial ATP synthesis. In addition, membrane Ca
2+
 ATPase activation, which is 
used to remove elevated intracellular Ca
2+
, causes an additional energetic demand on 
the neuron (Nicholls, 2009). A severe bioenergetic deficit may be in part responsible for 
the sensitization of Mfn2–knocked-down neurons to NMDA doses in the threshold of 
toxicity. There are other possible mechanisms by which Mfn2 reduction may contribute 
to neuronal vulnerability that are based on its unique properties. For example, Mfn2 
deficiency is associated with endoplasmic reticulum stress (Sebastián et al, 2012). 
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Another possibility is based on the capacity of Mfn2 to arrest the cell cycle in vascular 
smooth muscle cells via its p21
ras
 motif (Chen et al, 2004). In neurodegenerative 
diseases, as well as stroke, there is a noxious attempt to re-enter the cell cycle that is 
associated with neuronal death (Herrup & Yang, 2007). Whether Mfn2 could block this 
attempt to re-enter the cell cycle in neurons remains to be determined.  
 
Mfn2 is transcriptionally downregulated in excitotoxicity 
During recent years several groups have established the role of the 
ubiquitin/proteasomal system in stress-mediated Mfn2 degradation. Mitochondrial 
depolarization promotes Mfn2 ubiquitinylation and proteasomal degradation in a 
Parkin-dependent manner (Chan et al, 2011; Tanaka et al, 2010). In stress conditions 
JNK phosphorylates Mfn2 at Ser 27 which recruits the E3 ubiquiting ligase Huwe 1, 
leading to its ubiquitination and degradation (Leboucher et al, 2012). Although 
excitotoxicity causes both mitochondrial depolarization and JNK activation (Borsello et 
al, 2003; Nicholls, 2009; Soriano et al, 2008), the reduction in Mfn2 protein levels was 
not blocked by inhibiting the proteasome. We found that the main mechanism 
implicated in Mfn2 reduction acts at the transcriptional level and does not seem to 
depend on enhanced proteolysis since inhibiting transcription or translation does not 
further reduce Mfn2 levels.  We have shown that transcription factor MEF2 regulates 
basal Mfn2 transcription in neurons and that excitotoxicity-mediated MEF2 degradation 
(Li et al, 2001; Okamoto et al, 2002) results in transcriptional downregulation of Mfn2 
(Fig. 8). MEF2 transcription factors play a pivotal role in brain development, synapse 
development and neuronal survival. The genetic program regulated by MEF2 that 
controls synaptic remodeling has been characterized (Flavell et al, 2008) but although 
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many studies have pointed to the importance of MEF2 in supporting neuronal viability 
(Li et al, 2001; Mao et al, 1999; Okamoto et al, 2002), the precise target genes are 
poorly defined. Here we demonstrate that Mfn2 is a novel MEF2 target gene that can 
mediate its prosurvival function. 
 
Mitochondrial dynamics in neurodegeneration 
Mitochondrial dysfunction and excitotoxicity are common features of adult-onset 
neurodegenerative disorders such as Alzheimer’s, Parkinson’s and Huntington’s 
disease, some of them occurring primarily in the absence of genetic linkage. Alterations 
in mitochondrial dynamics have been reported in all these diseases (Itoh et al, 2013). 
Mfn2 is dynamically regulated, thus its misregulation could intervene in the 
pathogenesis of neurodegenerative disorders. Further studies are required to clarify the 
role of Mfn2 in the progression of chronic late-onset neurodegenerative disorders. 
During an ischemic episode, glutamate levels build up as a result of synaptic release and 
impaired and/or reversed uptake mechanisms, which induce excessive activation of 
NMDA glutamate receptors (NMDARs) and Ca
2+
 mediated cell death (Arundine & 
Tymianski, 2003). The evolution of ischemic injury is progressive, lasting for minutes, 
hours and even days.  The ischemic core refers to the irreversibly damaged tissue. 
Surrounding the ischemic core there is a damaged but potentially salvageable area 
termed the ischemic penumbra (Lo, 2008). Hence, the ischemic penumbra is the most 
clinically relevant therapeutic target. Currently the only approved treatment for acute 
ischemic stroke is thrombolysis with tissue plasminogen activator (tPA) administered 
within 4.5 hours of symptom onset (Zhang et al, 2012). It is of great importance to find 
novel targets to extend the therapeutic window. In this study we show that Mfn2 
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downregulation is a late event of excitotoxicity (4 hours after the excitotoxic insult). 
Neurons with reduced Mfn2 have dysfunctional mitochondria and altered Ca
2+
 
homeostasis. That makes neurons susceptible to excitotoxic damage and suggests that 
Mfn2 downregulation could determine the fate of neurons in the penumbra area. 
Thereby, Mfn2 is a potential therapeutic target against excitotoxicity in acute episodes 
and chronic neurodegenerative diseases.  
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Materials and methods 
Cell culture, transfection and determination of cell death 
 Cortical neurons from E21 Sprague Dawley rats were cultured as described previously 
(Soriano et al, 2008). Experiments were performed after a culturing period of 10–11 
days during which cortical neurons develop a rich network of processes, express 
functional NMDA-type and AMPA/kainate-type glutamate receptors, and form synaptic 
contacts. Prior to stimulations and transfections, neurons were transferred from growth 
medium to a medium containing 10% MEM (Invitrogen), 90% salt-glucose-glycine 
(SGG) medium (SGG: 114 mM NaCl, 0.219 % NaHCO3, 5.292 mM KCl, 1 mM 
MgCl2, 2 mM CaCl2, 10 mM HEPES, 1 mM glycine, 30 mM glucose, 0.5 mM sodium 
pyruvate, 0.1% phenol red; osmolarity 325 mosm/l). Transfections were performed with 
Lipofectamine 2000 (Invitrogen). For cell death determination neurons transfected with 
GFP plus the indicated expression vectors were treated with NMDA for 6 hours and 
fixed. Nuclei were stained with DAPI and cell death was determined by counting the 
number of DAPI-stained pyknotic nuclei as a percentage of the total transfected 
neurons.  
10T1/2 and HeLa cells were maintained in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum in subconfluent cultures. Transfections were 
performed with either Lipofectamine 2000 (Invitrogen) or Fugene (Roche). 
Focal ischemia model 
All animal procedures were in compliance with the directives of the Swiss Academy of 
Medical Science and were authorized by the veterinary office of the Canton of Vaud. 
Anesthesia was induced with 2.5% isoflurane in a chamber and maintained during the 
operation with a mask using 2.5% isoflurane. Middle cerebral artery occlusion was 
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performed in 12-day-old male Sprague-Dawley rats as previously described (Vaslin et 
al, 2009). Briefly, after the skin incision, a small piece of bone was removed from over 
the main (cortical) branch of the left middle cerebral artery, which was 
electrocoagulated just below its bifurcation into the parietal and frontal branches. The 
left common carotid artery was then occluded with a clip for 90 minutes. Rat pups were 
maintained at 37°C in the induction chamber (2.5% isoflurane) while the left common 
carotid artery was occluded. The arterial clip was then removed, and the restoration of 
carotid blood flow was verified under a dissecting microscope before the skin incision 
was closed using tissue adhesive (Histoacryl, B. Braun, Tuttlingen, Germany). Rat pups 
were transferred back to their mother until sacrifice. 
Rat pups were decapitated and the brains were removed in PBS containing 1 mmol/L 
MgCl2 on ice. The cortex were dissected and collected in protein hypotonic lysis buffer 
(20 mmol/L HEPES, pH 7.4, 10 mmol/L NaCl, 3 mmol/L MgCl2, 2.5 mmol/L EGTA, 
0.1 mmol/L dithiothreitol, 50 mmol/L NaF, 1 mmol/L Na3VO4, 1% Triton X-100, and a 
protease inhibitor cocktail (Roche)). Tissues were homogenized and sonicated, and 
protein concentration was determined using the Bradford assay. 
Plasmids and virus generation 
The following plasmids have been described previously: the -1982/+45 Mfn2-
Luciferase vector and its 5’ deletion constructs (Sorianello et al, 2012), SESN2-Luc  
(Papadia et al, 2008), and mtRFP (Legros et al, 2002). HA-Mfn2 was subcloned into the 
pEF vector at the BamHI/XbaI sites.  The MEF2A expression vector was a gift from 
Pilar Ruiz-Lozano (Stanford University, USA), GFP-Drp1 was a gift from AM van der 
Bliek (UCLA, USA), Drp1-K38A-myc was Addgene plasmid 26049, deposited by Dr. 
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Chan, and Mfn2-myc was Addgene plasmid 23213, deposited by Dr. Chan (Chen et al, 
2003)).  
The vectors used to construct and package recombinant adeno-associated viruses 
(rAAVs) were provided by Dr. Bading (U. Heidelberg, Germany (Zhang et al, 2007)). 
For construction of pAAV-MEF2-DN the first 252 bp of the mouse MEF2D cDNA (a 
gift from E. Olson; U. Texas South Western, USA) were amplified using the primers: 
forward 5’- ATA GGA TCC ATG GGG CGA AAG AAG ATA CAA ATC ACA CGC 
ATA ATG GAT G -3’ and reverse 5’- ATA AAG CTT TCA CAG ATC TTC TTC 
AGA AAT AAG TTT TTG TTA GGA GGG CCT CGT TTG AAA ATA AAA TC -
3’. The amplified product contains sequences that produce BamHI and HindIII 
restriction sites at the 5’ and 3’ respectively (italics) and also for inserting a myc tag 
into the C terminus (bold). GFP in the rAAV-GFP vector was removed by 
BamHI/HindIII digestion and the MEF2-DN PCR product was cloned into the rAAV 
vector to express the first 84 amino acids of the N terminus of MEF2, which contains 
the DNA binding domain but not the transactivation domain. rAAV for shRNA 
expression contains the U6 promoter for shRNA expression and a CMV/chicken beta-
actin hybrid promoter driving hrGFP expression. rAAV-shRNA targeting Mfn2 were 
made by swapping the sh-sc sequence of rAAV-sh-sc (gift from H. Bading) for the 
following sequences of the rat Mfn2 into the BamHI and HindIII sites: shMfn2: 5’-
AGA GGG CCT TCA AGC GCC AGT-3’, shMfn2.2: 5’- GGG AAG AGC ACC GTG 
ATC AAT-3’, shMfn2.3: 5’- TCC TCA AGG TTT ATA AGA ATG-3’. All newly 
generated constructs were confirmed by sequencing.  
Neurons were infected with rAAV at DIV4. Infection efficiencies were determined at 
DIV 10-11 by analyzing GFP fluorescence or immunocytochemical analysis; they 
ranged from 80 to 90% of the viable neurons. 
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Site-directed mutagenesis  
Site-directed mutagenesis was performed using the QuikChange
®
 Site-Directed 
Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions. The mutated 
sequences are shown in Fig. S5B. 
 
Luciferase assay 
Firefly luciferase-based reporter gene was transfected along with a Renilla expression 
vector (pTK-RL; Promega), and also, where relevant, MEF2-DN expression vector. 
Forty hours after transfection luciferase assays were performed using the Dual Glo 
assay kit (Promega) with Firefly luciferase-based reporter gene activity normalized to 
the Renilla control (pTK-RL plasmid) in all cases. 
 
RNA isolation, RT-PCR and qPCR 
RNA was isolated using an RNA extraction kit (Life Technologies). For qPCR, cDNA 
was synthesized from RNA using the SuperScript® III First-Strand Synthesis SuperMix 
(Life Technologies) according to the manufacturer’s instructions. qPCR was performed 
in a StepOne Real-Time PCR System (Applied Biosystem) using GoTaq QPCR Master 
Mix (Promega) according to the manufacturer’s instructions. The primers used were: 
Mfn2 -F: 5’- ATG TCA AAG GGT ACC TGT CCA-3’, -R: 5’- CAA TCC CAG ATG 
GCA GAA CTT-3’;  SESN2 -F: 5’- GGA TTA TAC CTG GGA AGA CC -3, -R:  5’- 
CGC AGT GGA TGT AGT TCC -3’; Mfn1 –F: 5’-CAA ACT GCA GCC ACC AAG 
T-3’, -R: 5’- GTT GGC ACA GTC GAG CAA-3’; 18S -F: 5’-GTG GAG CGA TTT 
GTC TGG TT-3’, -R: 5’-CAA GCT TAT GAC CCG CAC TT-3’. Expression of the 
gene of interest was normalized to 18S, a commonly used control.  
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Western blotting and antibodies 
Total cell lysates were boiled at 100°C for 5 min in 1.5x sample buffer (1.5 M Tris pH 
6.8; Glycerol 15%; SDS 3%; β-mercaptoethanol 7.5%; bromophenol blue 0.0375%). 
Gel electrophoresis was performed using 10% polyacrylamide gels. The gels were 
blotted onto PVDF membranes, which were then blocked for 1 hour at room 
temperature with 5% (w/v) non-fat dried milk in TBS with 0.1% Tween 20. The 
membranes were then incubated at 4°C overnight with the primary antibodies diluted in 
blocking solution:  anti-Mfn2 (1:2000; Abcam), Mfn1 (1:250, Santa Cruz), Opa1 
(1:1000; BD Biosciences), Drp1 (1:1000, BD Biosciences), MEF2A (1:750, Santa 
Cruz), Jun (1:1000, BD Biosciences), Actin (1:10000, Sigma) and Porin (1:100000, 
Abcam).   For visualization of Western blots, HRP-based secondary antibodies were 
used followed by chemiluminescent detection on Kodak X-Omat film. Western blots 
were analyzed by digitally scanning the blots, followed by densitometric analysis 
(ImageJ). All analyses involved normalizing to a loading control, Actin and Porin. 
 
 Imaging studies  
Cells were visualized using a TCS SP2 Leica confocal laser scanning microscope (Leica 
Lasertechnick GmbH, Mannheim, Germany) adapted to an inverted Leitz DMIRBE 
microscope at 37ºC in a controlled 5% CO2 atmosphere (Life Imaging Services). 
Pictures were acquired using a 63X (1.32 NA) Leitz Plan-Apochromatic objective. 
Images were analyzed using ImageJ software (Rasband, W.S., 1997-2012). 
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To quantify mitochondrial membrane potential neurons were loaded with 20 nM 
tetramethylrhodamine methylester (TMRM; Sigma) in SGG medium without phenol 
red. Transfected cells were identified by co-transfecting GFP expression plasmid.   
Single cells were monitored, TMRM was excited at 540 nm and emission was measured 
using a 570 nm filter. The mitochondrial membrane potential was compared to that 
observed in surrounding untransfected neurons and subsequently expressed as a 
percentage of that observed in untransfected cells before NMDA stimulation. 
 For mitochondrial morphology analysis neurons were transfected with mitochondrially 
targeted RFP. After treatment neurons were fixed, and nuclei were stained with DAPI.  
The number of live neurons with tubular or fragmented mitochondria was counted. 
Drp1 localization was determined by transfecting cortical neurons with GFP-Drp1 and 
mtRFP. Forty-eight hours after transfection neurons were treated when appropriate with 
30 M NMDA and fixed.  
 
Measurement of cytoplasmic Ca
2+
 
AAV-sh-sc- or AAV-sh-Mfn2-transduced neurons were loaded with 5 M of the 
ratiometric Ca
2+
 indicator Indo-1 for 30 minutes at 37ºC in SGG medium without 
phenol red. After two washes with PBS neurons were incubated for 15 additional 
minutes in order to allow de-esterification of Indo-1. Neurons were excited at 350 nm 
and the ratio of the emitted fluorescence values at 405 (Indo-1 Ca
2+
 bound) and 485 nm 
(Indo-1 Ca
2+
 free) was used as an index of [Ca
2+
].  
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Chromatin immunoprecipitation (ChIP) 
Two 60 mm dishes were used for each treatment (approx 4.5 x 10
6
 cells). Medium was 
removed and treated cells were washed with pre-warmed medium and incubated for 10 
minutes at room temperature with 1% para-formaldehyde in pre-warmed medium, to 
crosslink proteins to DNA. The reaction was stopped by adding glycine to a final 
concentration of 125 mM for 5 min. Cells were washed twice with ice-cold PBS and 
harvested on ice in swelling buffer (25% HEPES pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 
0.1% NP40 plus protease inhibitor cocktail set III (Calbiochem)). Nuclei were isolated 
using a douncer and centrifuging at 1500 g for 5 minutes. Nuclei were resuspended in 
200 µl sonication buffer (50 mM Hepes pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% 
Triton X100, 0.25% NaDeoxicolate, 0.1% SDS plus protease inhibitors). The nuclei 
were sonicated using a Diagenode Bioruptor (Liege, full power 30 s on, 30 s off, in an 
ice bath for 20 min) to produce fragments < 500 bp. Sonicated chromatin was 
precleared with protein-A agarose beads/salmon sperm DNA for 1 h at 4°C with 
agitation, beads were collected by centrifugation  and supernatants were collected and 
subjected to immunoprecipitation. Eight micrograms of anti-MEF2 (Santa Cruz) or anti-
Rabbit IgG (control, Sigma) was added for overnight incubation at 4ºC with agitation.  
After chromatin immunoprecipitation, DNA was precipitated using Qiagen DNA 
purification columns. Input (1% of total immunoprecipitated) and immunoprecipitated 
DNA were subjected to qPCR analysis with primers amplifying the Mfn2 promoter (-
2204/-2136  of the rat Mfn2 promoter) 5’-TGG AGA TGG AAT TCA AGT TGG-3’ 
forward and 5’-TGGTCACAAAATGGCTCAGT-3’ reverse. As negative controls we 
used primers for amplification of the actin gene 5’-AGC CAT GTA CGT AGC CAT 
CC-3’ forward and 5’-CTC TCA GCT GTG GTG GTG AA-3’ reverse. 
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For binding to the human Mfn2 promoter, input and immunoprecipitated DNA were 
subjected to PCR analysis using the primers 5’-GTG CAG TGG CAT GAT CTC GGC 
TCA-3’ and 5’-GGC GAG GCG GGT GCA TCG GGA GTT-3’, which flank the MEF2 
site on the human Mfn2 promoter, and the primers 5’-CAA ATG CTG GAC CCA ACA 
CAA-3’ and 5’-CCT CCA CAA TAT TCA TGC CTT CTT-3’, which flank a region of 
human cyclophilin gene. 
Electrophoretic mobility-shift assays  
HeLa cells were transfected with expression vector for MEF2A and 48 hours later, 
nuclear extracts were prepared as described previously (Santalucia et al, 2001). 
Radiolabeled double strand oligonucleotide probe containing the human Mfn2 promoter 
sequence (containing the MEF2 binding site: 5’-ATT TTT GTA TTT TTA GTA CAG-
3’ (MEF2wt), the mutated MEF2 binding site (in bold), which differs from the wild 
type in the same three nucleotides used in the luciferase assay: 5’-ATT TTT GGA TCC 
TTA GTA CAG-3’ (MEF2mut), and the MEF2 binding site in the Glut4 promoter: 5’- 
CGT GGG AGC TAA AAA TAG CCA-3’ (MEF2Glut4) was incubated with 10 μg 
nuclear extract in a final volume of 20 μl  and electrophoresis was performed as 
described previously (Santalucia et al, 2001). Dried gel was exposed to Kodak film. 
Competitor mutated oligonucleotide differed from wild-type EMSA sequence by the 
same base substitution used in the functional experiments. For supershift assays, MEF2 
antibody was added to the corresponding binding reactions after incubation with the 
radiolabeled probe, and incubated for a further 10 minutes at room temperature before 
loading onto gels. 
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Statistical analysis 
Statistical testing involved two-tailed student T-tests. For any multiple comparisons 
within data sets we used a one-way ANOVA followed by the Bonferroni post-hoc test. 
All data are presented as mean ± s.e.m. of at least three independent experiments. 
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Figure legends 
 
Figure 1. Mfn2 expression is reduced in excitotoxicity in vitro and in vivo. Western 
analysis of mitochondrial fusion/fission proteins. A) In vitro primary cortical neurons 
exposed to NMDA (30 M) for the indicated times and (B) densitometric analysis 
normalized to actin  (n=3–6).  C) In vivo brain extracts of rats subjected to MCAO plus 
90 minutes of ipsilateral carotid clamp followed by clamp release for the indicated times 
and (D) densitometric analysis normalized to actin  (n=3–7). Mean ± s.e.m. in this and 
subsequent cases. *p<0.05 compared to control, two-tailed T-test.  
 
Figure 2. Activation of Drp1 induces mitochondrial fragmentation. A) 
Representative images of neurons transfected with plasmid encoding 
mitochondriatargeted RFP (mtRFP) showing tubular or fragmented mitochondria.  The 
white box indicates the high magnification area. Arrowhead points to the transfected 
neuron. Scale bar = 20 m. B) Time-course of NMDA-induced mitochondrial 
fragmentation. Neurons transfected with mtRFP were treated with NMDA (30 M) for 
the indicated times and mitochondrial morphology was analyzed (n=3-8). *p<0.05 
compared to control, one-way ANOVA followed by Bonferroni post hoc test.  C) 
NMDA induces increased Drp1 translocation to mitochondria. Neurons were transfected 
with plasmids encoding GFP-Drp1 and mtRFP. After 48 h neurons were stimulated with 
NMDA (30 M) for 1 hour or left unstimulated, fixed and visualized under a confocal 
microscope. Brightness and contrast has been adjusted in the merged image to visualize 
GFP signal in the control condition. Scale bar yellow = 20 m, white = 4 m. D) 
Genetic and pharmacological inhibitors of Drp1 block mitochondrial fragmentation.  
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Neurons were transfected with plasmids encoding mtRFP and Drp1-K38A or control  
(globin). After 48 hours neurons were stimulated with NMDA (30 M) for 1 hour and 
mitochondrial morphology was analyzed (n=3) or they were pre-treated for 1 hour 
before NMDA stimulation with mdiv-1 (25 M) or 7-Nitroindazole ((7-Ni) at 5 M in 
Arg free medium). *p<0.05, one-way ANOVA followed by Bonferroni post hoc test.  
 
Figure 3. Mfn2 intervenes in an irreversible delayed phase of mitochondrial 
fragmentation. A) Secondary mitochondrial fragmentation after NMDA wash-out. 
Neurons were transfected with mtRFP. After 48 h neurons were stimulated with NMDA 
(30 M) for 1 hour and washed out for the indicated times and mitochondrial 
morphology was analyzed (n=4–5). *p<0.05, one-way ANOVA followed by Bonferroni 
post hoc test. B) Mfn2 is reduced after NMDA wash-out. Western and densitometric 
analysis of neurons treated with NMDA (30 M) for 1 hour and washed out for 3 
additional hours (n=4). *p<0.05, two-tailed T-test. C) Representative western blot and 
densitometric analysis of neurons transduced with AAV producing shRNA against 
Mfn2 or scrambled (n=4). *p<0.05, one-way ANOVA followed by Bonferroni post hoc 
test. D) Mfn2 knockdown causes mitochondrial fragmentation. Analysis of 
mitochondrial morphology of neurons transfected with plasmids shMfn2 or sh-sc and 
mtRFP  (n=4). *p<0.05, two-tailed T-test. E) Mfn2 blocks the delayed phase of NMDA-
induced mitochondrial fragmentation. Neurons transfected with plasmids encoding 
mtRFP and Mfn2 or globin (CT) were treated with NMDA (30 M) for 1 hour and 
washed out for 3 additional hours and mitochondrial morphology was analyzed (n=3). 
*p<0.05, one-way ANOVA followed by Bonferroni post hoc test.   
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Figure 4 Mfn2 downregulation causes mitochondrial dysfunction and altered Ca
2+
 
homeostasis and sensitizes neurons to excitotoxic damage. A) Loss of mitochondrial 
membrane potential in neurons transfected with sh-Mfn2 or sh-sc and treated with 
NMDA (15 M; arrow) was determined by measuring TMRM fluorescence. The values 
were normalized to surrounding untransfected neurons (n=19–21 neurons analyzed in 
five independent experiments). *p<0.05, two-tailed T-test. B) Determination of 
intracellular Ca
2+
 in cortical neurons transduced with AAV producing sh-Mfn2 or sh-sc 
and treated with NMDA  (15 M) (n=3). C) Histograms show the average intracellular 
Ca
2+
 levels 20 minutes before and after NMDA application (15 M) (n=3). *p<0.05, 
one-way ANOVA followed by Bonferroni post hoc test. D) Neurons transfected with 
plasmids expressing sh-Mfn2 or sh-sc were treated with subtoxic doses of NMDA (15 
M) for 6 hours. Death was analyzed by fixing cells, DAPI-staining and counting 
pyknotic nuclei of the transfected neurons (n=5). *p<0.05, two-tailed T-test.  
 
Figure 5. Mfn2 is regulated at transcriptional level in excitotoxicity. Cortical 
neurons with or without pre-incubation with proteasome inhibitor MG-132 (10 M) 
were treated for 4 hours with NMDA (30 M) and Mfn2 levels were analyzed by 
western blot. A) Representative western and B) densitometric analysis (n=7). *p<0.05, 
one-way ANOVA followed by Bonferroni post hoc test. C) Cortical neurons were 
treated with NMDA (30 M) for the indicated times and mRNA expression was 
determined by real time qPCR.   (n=4). *p<0.05, two-tailed T-test. Cortical neurons 
were treated with transcriptional inhibitor actinomycin D, translational inhibitor 
cycloheximide and NMDA (30 M) for 4 hours as indicated and Mfn2 protein 
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expression was analyzed by western blot. D) Representative western and E) 
densitometric analysis (n=4). *p<0.05, two-tailed T-test. 
 
Figure 6. Excitotoxicity-mediated Mfn2 downregulation depends on MEF2. Time 
course of excitotoxicity dependent MEF degradation (A) in cortical neurons in vitro 
treated with NMDA (30 M) for 4 hours and (B) brain extracts of rats subjected to 
MCAO plus 90 minutes of ipsilateral carotid clamp followed by clamp release for the 
indicated times. C) Cortical neurons transduced with AAV expressing MEF2-DN have 
lower Mfn2 levels than AAV-GFP or non transduced neurons. D) Mitochondrial 
morphology in cortical neurons transfected with the indicated expression vectors (n=4–
5). *p<0.05, one-way ANOVA followed by Bonferroni post hoc test.  E) Mitochondrial 
membrane potential of neurons expressing the indicated vectors (n=9 cells from three 
independent experiments). F) Cortical neurons transduced with AAV expressing MEF2-
DN or GFP (control) were treated with NMDA (30 M) for 4 hours and Mfn2 mRNA 
expression was determined by qRT-PCR (n=5). *p<0.05, one-way ANOVA followed 
by Bonferroni post hoc test.  
Figure 7. MEF2 directly regulates basal Mfn2 expression in neurons. A) Luciferase-
based reporter of Mfn2 promoter in cortical neurons (left) or 10T1/2 cell line (right) and 
SESN2 promoter in cortical neurons (center) in control or over-expressing MEF2-DN 
(n=3-9). *p<0.05 compared to control, two-tailed T-test. B) Deletion analysis of a 
luciferase-based reporter of the Mfn2 promoter in 10T1/2 cells co-expressed with 
control or MEF2 plasmids (n=3). *p<0.05, two-tailed T-test. C) Effect of putative 
MEF2 binding site mutations on MEF2-dependent induction of the Mfn2 promoter in 
10T1/2 cells  (n=3). *p<0.05 compared to control, two-tailed T-test. D) EMSA 
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performed with nuclear extracts of HeLa cells overexpressing MEF2 and radiolabeled 
probe encoding BOX 2 from Mfn2 promoter. Retardation complexes are indicated with 
arrows. Excess of cold oligonucleotide, mutated oligonucleotide or oligonucleotide of 
the Glut4 gene that contains a MEF2 binding site was used to compete. Radiolabeled 
probe containing mutated BOX 2 did not produce retardation complexes. E) Supershift 
was performed using MEF2 polyclonal antibody. Pre-immune serum was used as a 
negative control.* indicates nonspecific binding of the probe to MEF2 antibody. F) 
HeLa cells were transfected with a MEF2A expression vector or an irrelevant 
expression vector (CT). ChIP carried out using MEF2A polyclonal antibody. Pre-
immune serum was used as a negative control. The input and immunoprecipitated DNA 
was used as a template for PCR with primers flanking the BOX 2 site on the Mfn2 gene. 
Primers amplifying a region of cyclophilin gene were used as the negative control. G) 
ChIP in cortical neurons untreated or treated with NMDA (30 M) for 4 hours using the 
indicated antibodies (n=4). *p<0.05, one-way ANOVA followed by Bonferroni post hoc 
test.  
 
Figure 8.  Proposed model for the changes in mitochondrial morphology and 
vulnerability in excitotoxic conditions. Under basal conditions MEF2 binds Mfn2 
promoter and regulates its gene expression resulting in mainly tubular mitochondria. In 
excitotoxic conditions Drp1 translocates to mitochondria and mediates rapid, reversible 
mitochondrial fission. An increase in cytosolic Ca
2+
 produces MEF2 degradation and 
Mfn2 gene expression is consequently downregulated, producing a delayed long term 
effect on mitochondrial morphology. Reduced expression of Mfn2 impairs 
mitochondrial function, which causes dysregulation of Ca
2+
 homeostasis and sensitizes 
neurons to subtoxic excitotoxic insults. 
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Supplementary Figure S1.  Densitometric analysis normalized to porin of western blots   of the indicated 
mitochondrial fusion/fission proteins: A) in vitro primary cortical neurons exposed to NMDA (30 µM) for the 
indicated times (n=3–6). B) In vivo brain extracts of rats subjected to MCAO plus 90 minutes of ipsilateral 
carotid clamp followed by clamp release for the indicated times (n=3–7). *p<0.05 compared to control, 
two-tailed T-test.
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Supplementary Figure S2.  A) Representative images of neurons transfected with mtRFP plus plasmids produ-
cing sh-sc or sh-Mfn2. White arrowheads indicate the transfected neurons. Scale bar=20 µm. B) HEK293 cells 
were transfected with plasmids encoding HA-Mfn2 plus shRNA targeted against different sequences of Mfn2 
(sh-Mfn2) or sh-sc. After 48 hours protein was harvested and subjected to western blot. C) Analysis of mitochon-
drial morphology in neurons expressing different sh-Mfn2 or sh-sc (n=3). *p<0.05, two-tailed T-test.
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Supplementary Figure S3.  A) Representative western blot showing spectrin full length (spectrin-FL) and spectrin 
cleaved (spectrin-clev.) in neurons expressing sh-sc or sh-Mfn2 after 30 minutes of treatment with subtoxic NMDA 
(15 µM). B) Cortical neurons were transfected with plasmids expressing sh-Mfn2 or sh-sc. After 48 hours neurons 
were treated with NMDA (15 µM) for 6 hours. Neuronal death was analyzed (n=6). *p<0.05, two-tailed T-test.  C) 
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by Bonferroni post hoc test. D) NMDA-dependent cell death in neurons expressing control (globin) or Mfn2 plas-
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Supplementary Figure S4.  A) MG-132 promotes accumulation of ubiquitinated proteins in neurons. 
Western blot showing ubiquitinated proteins in cortical neurons after 4 hours of treatment with 10 µM 
MG-132. Actin was used as a loading control. B) CCCP dependent degradation of Mfn2 is blocked by the 
proteasome inhibitor MG-132. Cortical neurons were treated with CCCP (10 µM) for 1 h in the absence 
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Supplementary Figure S5. A) Western blot analysis to compare the expression of the indicated prote-
ins in primary cortical neurons and 10T1/2 cells. B) Sequence of the two putative MEF2 binding sites 
found in the Mfn2 human promoter. The mutations of these sequences are in lower case. C) Sequence 
of the region between -2352/-1392 with respect to the transcription start site of the Mfn2 rat promoter. 
Shown in red are the putative MEF2 binding sites found using the PROMO and Patch public 1.0 
programs. The region amplified in the ChIP experiments is shaded.
